1-3 of 3
Brendan Hodkinson
Close
Sort by
Journal Articles

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

Clinical Trials & Observations
Peter W. M. Johnson, Sriram Balasubramanian, Brendan Hodkinson, S. Martin Shreeve, Steven Sun, Srimathi Srinivasan, Andrew J. Steele, Jessica Vermeulen, Laurie H. Sehn, Wyndham H. Wilson
Journal: Blood Advances
Blood Adv (2023) 7 (10): 2008–2017.
https://doi.org/10.1182/bloodadvances.2022009389
Published: 2023
Includes: Supplemental data
Journal Articles

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

Findlay Bewicke-Copley, Koorosh Korfi, Shamzah Araf, Brendan Hodkinson, Emil Kumar, Thomas Cummin, Margaret Ashton-Key, Sharon Barrans, Suzan van Hoppe, Cathy Burton, Mohamed Elshiekh, Simon Rule, Nicola Crosbie, Andrew Clear, Maria Calaminici, Hendrik Runge, Robert K. Hills, David W. Scott, Lisa M. Rimsza, Geetha Menon, Chulin Sha, John R. Davies, Ai Nagano, Andrew Davies, Daniel Painter, Alexandra Smith, John Gribben, Kikkeri N. Naresh, David R. Westhead, Jessica Okosun, Andrew Steele, Daniel J. Hodson, Sriram Balasubramanian, Peter Johnson, Jun Wang, Jude Fitzgibbon
Journal: Blood Advances
Blood Adv (2023) 7 (5): 845–855.
https://doi.org/10.1182/bloodadvances.2022007536
Published: 2023
Includes: Supplemental data
Journal Articles

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

Alessio Bruscaggin, Lodovico Terzi di Bergamo, Valeria Spina, Brendan Hodkinson, Gabriela Forestieri, Ferdinando Bonfiglio, Adalgisa Condoluci, Wei Wu, Maria C. Pirosa, Martin R. Faderl, Ricardo Koch, Michael Schaffer, John D. Alvarez, Nele Fourneau, Bernhard Gerber, Georg Stussi, Emanuele Zucca, Sriram Balasubramanian, Davide Rossi
Journal: Blood Advances
Blood Adv (2021) 5 (22): 4674–4685.
https://doi.org/10.1182/bloodadvances.2021004528
Published: 2021
Includes: Supplemental data